Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Sage Therapeutics (SAGE) PT Lowered to $58 at Stifel
February 24, 2022 10:19 AM ESTStifel analyst Paul Matteis lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $58.00 (from $75.00) while maintaining a Buy rating.
The analyst commented, "We are maintaining our Buy rating on Sage following their 4Q21 update. Even with mixed CORAL data, we still... More
SAGE Therapeutics (SAGE) Tops Q4 EPS by 4c
February 24, 2022 6:39 AM ESTSAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($2.12), $0.04 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $1.64 million versus the consensus estimate of $1.97 million.
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
... More